Sector News

Novartis whacks 500 old-line jobs in Switzerland

May 19, 2017
Life sciences

It’s out with the old and in with the new as Swiss drugmaker Novartis slashes hundreds of jobs in areas like “traditional manufacturing” in and around its Basel headquarters over the next 18 months and adds jobs in high tech areas like biologics production.

In an emailed statement, the drugmaker reiterated its commitment to its home country even as it announced Thursday that it intended to eliminate 500 jobs in traditional manufacturing, coordination and development operations positions in the Basel area over the next year and a half, while adding 350 high-tech positions in “development and innovative biologics manufacturing.”

The cuts include plans to close production sites in Basel and at the Schweizerhalle industrial complex in canton Basel, according to Swissinfo, which reported some jobs are being transferred to India.

The company said the moves are part of the “ongoing global transformation” tied to a decision made last year to strengthen innovation and enhance quality and efficiency worldwide, but it is a process that has been going on longer than that for Novartis and the second time in recent years for it to do major revamp of jobs in Switzerland.

In 2014, after CEO Joe Jimenez pronounced his dissatisfaction with the company’s operating margins, the company said that it would cut 500 jobs in Switzerland from R&D and administrative functions while hiring another 500 or so Swiss workers for different positions in the pharma business, as well as generic drugs and over-the-counter products. Some of those jobs lost in Switzerland were shifted to an administrative services site in India that opened in 2015.

Last year, as its finances continued to lag, Jimenez took aim at R&D. Among other shifts and cuts, it announced plans to move its Singapore research base for dengue fever and malaria over to California, and to reduce headcount at its Zurich facility and its China biologics group.

All of this cutting, nipping and tucking may be paying off for the company. It turned in some surprisingly good numbers in the first quarter, leading some analysts to speculate publicly that it might have gotten past the worst of its problems. In the quarter, it saw sales out of its generics operation Sandoz and its struggling Alcon eye unit, but new drugs like psoriasis-fighter Cosentyx and heart failure med Entresto helped the company exceed revenue expectations at $11.54 billion. Core EPS also beat, at $1.13 to the Street’s $1.11.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.